Cancer Risk for Patients Using Thiazolidinediones for Type 2 Diabetes: A Meta-Analysis
Article 2013 en
Authors
CB
Cristina Bosetti
VR
Valentina Rosato
DB
Danilo Buniato
Abstract
1 min read
Adequate evidence excludes an overall excess cancer risk in TZD users within a few years after starting treatment. However, there is a modest excess risk of bladder cancer, particularly with reference to pioglitazone. Assuming that this association is real, the potential implications on the risk-benefit analysis of TZD use should be evaluated.
Davide Soranna, Lorenza Scotti, Antonella Zambon, Cristina Bosetti, Guıdo Grassı, Alberico L. Catapano, Carlo La Vecchia, Giuseppe Mancia, Giovanni Corrao
Chen Yuan, Xuehong Zhang, Ana Babić, Vicente Morales‐Oyarvide, Yin Zhang, Stephanie A. Smith‐Warner, Kana Wu, Molin Wang, Brian M. Wolpin, Jeffrey A. Meyerhardt, Andrew T. Chan, Frank B Hu, Charles S. Fuchs, Shuji Ogino, Edward L. Giovannucci, Kimmie Ng
Discussion(0)
No comments yet. Be the first to comment.